Shares of Verici Dx plc (LON:VRCI – Get Free Report) shot up 9.3% on Friday. The stock traded as high as GBX 0.25 and last traded at GBX 0.23. 56,845,227 shares changed hands during trading, an increase of 1,694% from the average session volume of 3,169,219 shares. The stock had previously closed at GBX 0.21.
Verici Dx Price Performance
The company has a market capitalization of £5.38 million, a price-to-earnings ratio of 2.35 and a beta of 1.22. The stock has a fifty day simple moving average of GBX 0.22 and a 200-day simple moving average of GBX 0.34. The company has a debt-to-equity ratio of 13.51, a current ratio of 2.82 and a quick ratio of 8.49.
Verici Dx Company Profile
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
See Also
- Five stocks we like better than Verici Dx
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
